日本および欧米におけるマーカー検査の内容

抄録

We investigated about flow cytometry (FCM) currently performed as a reference for standardizing immunophenotyping of hematologic neoplasia with 3 Commercial Clinical Laboratories in Japan, 3 cancer research institutes in the U.S.A., and 1 cancer research institute in Europe. Investigation followed quality control (QC) of the instrument, the cluster of differentiation (CD) panel, the gating method, and the data analyzing method. About QC, the method of managing mean fluorescence intensity (MFI) using a fluorescence bead in all institutions was taken. The fluorescence bead to be used had the institution which uses only CaliBRITE Beads, and the institution which is using together Rainbow Calibration Particle which can check five kinds of fluorescence peaks. About the CD panel, the feature was accepted by each purpose, diagnosis of the neoplasm cell before treatment, minimal residual disease (MRD) detection after treatment, monitoring of the mature process of the cell in bone marrow after treatment, and the analysis of a special case. About the gating method, FSC-SSC dot-plot gating and CD45 blast gating were used together with most of institutions. With a European institution, CD45 blast gating was not made indispensable. With one institution in the U.S.A., CD45 blast gating which used CD45 Log-SSC dot-plot was used. Although 2-dimensional analysis was performed with most of institutions about the data analyzing method, multi-dimension analysis was performed with two facilities in the U.S.A.. Establish the standard method of immunophenotyping of hematologic neoplasia is an important subject in order to raise the clinical meaning of FCM.